葫芦影

Computational Biologist Aids in Development of COVID-19 Drug Screening Tool

Assistant Professor Dinler Amaral Antunes Publishes Study Outlining Tool Development

In an effort to develop drugs to treat COVID-19, a team of multidisciplinary researchers created an online tool that can predict whether a drug molecule can be docked to a protein on the SARS-CoV-2 virus.

Results from DINC-COVID Webpage
Results from DINC-COVID webpage. Users can browse through different binding modes, visualize protein conformations or download all the results for further inspection.

Dinler Amaral Antunes, assistant professor of computational biology at the University of Houston, along with scientists from Rice University, Scotland鈥檚 University of Edinburgh and Brazil鈥檚 Federal University of Cear谩, collaborated to create the webserver . They published their work in the journal .

DINC, which stands for Docking INCrementally, is an online tool that can screen whether a drug can bind to a protein that鈥檚 being targeted for treatment. Antunes helped develop the tool while he was a postdoctoral researcher in the lab of Rice University computer science professor Lydia Kavraki.

At the beginning of the pandemic, Geancarlo Zanatta, a former collaborator from Brazil, who is now associate professor at the Federal University of Cear谩, reached out to Antunes saying many researchers were attempting to run virtual screenings for drugs that could be used to treat COVID-19, without much success. Zanatta said one of the issues researchers were not considering was the flexibility of the protein receptor.

Map
More than 500 users from 54 countries have used DINC-COVID thus far.

鈥淴-Ray crystallography, the experimental method for protein structure determination, provides a 鈥榮tatic picture鈥 of the protein structure,鈥 said Antunes, faculty at UH鈥檚 College of Natural Sciences and Mathematics. 鈥淗owever, proteins have dynamic behavior in solution. They can oscillate between states and that has a direct impact on the shape of the binding sites available for drug interaction.鈥

For example, the team writes that although SARS-CoV-2鈥檚 Main protease (Mpro) has so far been one of the most explored coronavirus targets in computational studies, there are still many questions about the design of inhibitors or drugs to treat the virus. 鈥淭he malleability of the Mpro active-site cavity remains the greatest challenge in the development of effective inhibitors,鈥 the study鈥檚 authors write.

To account for the protein flexibility, the team made DINC-COVID, a version of DINC built specifically to test drugs鈥 ability to dock to multiple conformations of SARS-CoV-2 proteins. The webserver uses molecular dynamics simulations to produce a 鈥渕ovie鈥 of the motions of proteins. Researchers then extract representative 鈥減ictures鈥 of what was captured by the movie, and they offer this ensemble for users to test the binding of their drug candidates. Results are emailed to the users.

DINC-COVID Available to Users Without Computational Expertise

鈥淢ore than 500 people have used the server from 54 different countries,鈥 Antunes said. 鈥淭here are people all over the globe using the tool right now for predictions and trying to find other protein binders.鈥

Simulating molecular dynamics is time consuming and requires high-performance computers. It limits the ability to dock multiple protein conformations to researchers who have these resources. Antunes is proud of the accessibility and ease their tool provides to people anywhere in the world with an internet connection. DINC-COVID enables both people with limited computational resources and people who do not have a computational background to test their own molecules, he said.

The paper鈥檚 authors note that although vaccines have been validated and used in massive vaccination campaigns, particularly in developed countries, 鈥渢he need for pharmacological treatments for infected patients persists due to unequal vaccination coverage across the globe鈥 and because of 鈥渢he rise of more virulent variants that can cause symptoms even in fully-vaccinated individuals.鈥

Their challenge during the beginning of the pandemic was to hopefully create a solution with their expertise.

鈥淢ost of my work is basic research,鈥 Antunes said. 鈥淚鈥檓 developing methods and potentially drugs that could come to market in several years, in the best-case scenario. Even with the vaccine results, there鈥檚 still room for drugs to help treat patients. That鈥檚 exciting. This is one case in which we will get close to make a direct impact, although we are on the prediction side.鈥

Other research groups can make their own predictions using DINC-COVID as a baseline and then test results in the lab to see if the findings are working as expected. Antunes is not aware of any drugs that have been developed using the tool yet.

Speedy Development Thanks to Broad Range of Subject Matter

The study included researchers from a variety of disciplines, ranging from biophysics to computer science to biochemistry.

鈥淭his enabled us to be slightly faster,鈥 he said. 鈥淢any of these research topics are complex and too difficult for one person to tackle all aspects of it. It鈥檚 important to do these collaborations with people who have different expertise to make progress more quickly.鈥

Future plans for DINC-COVID include expansion of the number of proteins available to work with on the webserver.

The study was funded by the National Science Foundation, Brazil鈥檚 National Council for Scientific and Technological Development, and Rice University.

- Rebeca Trejo, College of Natural Sciences and Mathematics

Top Stories